Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...

Vertex Pharmaceuticals has shared data from the Phase I/II segment of the Phase I/II/III FORWARD-101 trial, evaluating ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial.

Lundbeck’s Vyepti (eptinezumab) has met both the primary and secondary endpoints in the placebo-controlled Phase IV ...

An expert from a CRO-SMO outlines Japan's advantages as a potential clinical trial site, in terms of services and regulatory ...

Patient-centric approaches such as AI and decentralised trials are improving oncology trial enrolment, but 2025 has given ...

Dizal has completed subject enrolment for the randomised Phase III WU-KONG28 trial of oral sunvozertinib for treating NSCLC ...

At the 15th Annual Outsourcing in Clinical Trials (OCT) Europe conference, which took place between 29 and 30 April in ...

Ventyx Biosciences has reported encouraging top-line outcomes from its Phase IIa trial of VTX3232 for early-stage Parkinson's ...

Biogen has commenced dosing in the Phase III BRAVE study of omaveloxolone in children of two-< 16 years of age with ...

Lyell Immunopharma has reported new clinical data from the Phase I/II clinical trial of CAR T-cell product candidate, LYL314.